Differential opioid action on sensory and affective cerebral pain processing

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 577-588

  Oertel, B G ^a   Preibisch, C ^a   Wallenhorst, T ^a   Hummel, T ^b   Geisslinger, G ^a   Lanfermann, H ^a   Lotsch J ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CARBON DIOXIDE; MU OPIATE RECEPTOR; PROTEIN OPRM1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC VARIABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; NOSE MUCOSA; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SOMATOSENSORY CORTEX; VOMITING;

ADULT; AFFECT; ALFENTANIL; ANALGESICS, OPIOID; CARBON DIOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACIAL PAIN; FEMALE; HETEROZYGOTE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; RECEPTORS, OPIOID, MU; REFERENCE VALUES; SOMATOSENSORY CORTEX; TRIGEMINAL NERVE;

EID: 40949132164     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100441     Document Type: Article

References (71)

1. Coghill, R.C., Sang, C.N., Maisog, J.M. & Iadarola, M.J. Pain intensity processing within the human brain: a bilateral, distributed mechanism. J. Neurophysiol. 82, 1934-1943 (1999).
2. Baumgartner, U. et al. High opiate receptor binding potential in the human lateral pain system. NeuroImage 30, 692-699 (2006).
3. Borsook, D. & Becerra, L.R. Breaking down the barriers: fMRI applications in pain, analgesia and analgesics. Mol. Pain 2, 30 (2006).
4. Wise, R.G., Williams, P. & Tracey, I. Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology 29, 626-635 (2004).
5. Tracey, I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J. Clin. Pharmacol. (suppl.), 21S-28S (2001).
6. Becerra, L., Breiter, H.C., Wise, R., Gonzalez, R.G. & Borsook, D. Reward circuitry activation by noxious thermal stimuli. Neuron 32, 927-946 (2001).
7. Leppa, M. et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. NeuroImage 31, 661-669 (2006).
8. Ogawa, S. et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc. Natl. Acad. Sci. USA 89, 5951-5955 (1992).
9. Logothetis, N.K. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357, 1003-1037 (2002).
10. Price, D.D., Von der Gruen, A., Miller, J., Rafii, A. & Price, C. A psychophysical analysis of morphine analgesia. Pain 22, 261-269 (1985).
11. Bond, C. et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA 95, 9608-9613 (1998).
12. Skarke, C., Kirchhof, A., Geisslinger, G. & Lotsch, J. Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin. Chem. 50, 640-644 (2004).
13. Hoehe, M.R. et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum. Mol. Genet. 9, 2895-2908 (2000).
14. Lötsch, J., Skarke, C., Grosch, S., Darimont, J., Schmidt, H. & Geisslinger, G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12, 3-9 (2002).
15. Romberg, R.R. et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102, 522-530 (2005).
16. Oertel, B.G., Schmidt, R., Schneider, A., Geisslinger, G. & Lotsch, J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 16, 625-636 (2006).
17. Drakenberg, K. et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc. Natl. Acad. Sci. USA 103, 7883-7888 (2006).
18. Klepstad, P. et al. The 118 A>G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48, 1232-1239 (2004).
19. Chou, W.Y., Wang, C.H., Liu, P.H., Liu, C.C., Tseng, C.C. & Jawan, B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105, 334-337 (2006).
20. Peyron, R., Laurent, B. & Garcia-Larrea, L. Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol. Clin. 30, 263-288 (2000).
21. Apkarian, A.V., Bushnell, M.C., Treede, R.D. & Zubieta, J.K. Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain 9, 463-484 (2005).
22. Bushnell, M.C., Duncan, G.H., Hofbauer, R.K., Ha, B., Chen, J.I. & Carrier, B. Pain perception: is there a role for primary somatosensory cortex? Proc. Natl. Acad. Sci. USA 96, 7705-7709 (1999).
23. Ferretti, A. et al. Functional topography of the secondary somatosensory cortex for nonpainful and painful stimulation of median and tibial nerve: an fMRI study. NeuroImage 23, 1217-1225 (2004).
24. 2 stimulation of nasal mucosa; a magnetoencephalographic study in man. Electroencephalogr. Clin. Neurophysiol. 64, 347-349 (1986).
25. Craig, A.D., Chen, K., Bandy, D. & Reiman, E.M. Thermosensory activation of insular cortex. Nat. Neurosci. 3, 184-190 (2000).
26. Bornhovd, K., Quante, M., Glauche, V., Bromm, B., Weiller, C. & Buchel, C. Painful stimuli evoke different stimulus-response functions in the amygdala, prefrontal, insula and somatosensory cortex: a single-trial fMRI study. Brain 125 (Part 6), 1326-1336 (2002).
27. Bingel, U., Quante, M., Knab, R., Bromm, B., Weiller, C. & Buchel, C. Subcortical structures involved in pain processing: evidence from single-trial fMRI. Pain 99, 313-321 (2002).
28. Gosselin, N. et al. Emotional responses to unpleasant music correlates with damage to the parahippocampal cortex. Brain 129 (Part 10), 2585-2592 (2006).
29. Fulbright, R.K. et al. Functional MR imaging of regional brain responses to pleasant and unpleasant odors. AJNR Am. J. Neuroradiol. 19, 1721-1726 (1998).
30. Derbyshire, S.W. A systematic review of neuroimaging data during visceral stimulation. Am. J. Gastroenterol. 98, 12-20 (2003).
31. Saper, C.B. Convergence of autonomic and limbic connections in the insular cortex of the rat. J. Comp. Neurol. 210, 163-173 (1982).
32. Vogt, B.A. Pain and emotion interactions in subregions of the cingulate gyrus. Nat. Rev. Neurosci. 6, 533-544 (2005).
33. Wise, R.G. et al. Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. NeuroImage 16, 999-1014 (2002).
34. Romberg, R., Olofsen, E., Sarton, E., Teppema, L. & Dahan, A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 99, 788-798 (2003).
35. Skarke, C., Darimont, J., Schmidt, H., Geisslinger, G. & Lotsch, J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73, 107-121 (2003).
36. Lötsch, J. & Geisslinger, G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. 11, 82-89 (2005).
37. Befort, K., Filliol, D., Decaillot, F.M., Gaveriaux-Ruff, C., Hoehe, M.R. & Kieffer, B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276, 3130-3137 (2001).
38. Beyer, A., Koch, T., Schroder, H., Schulz, S. & Hollt, V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 89, 553-560 (2004).
39. Zhang, Y., Wang, D., Johnson, A.D., Papp, A.C. & Sadee, W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280, 32618-32624 (2005).
40. Melzack, R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1, 277-299 (1975).
41. Bouillon, T. et al. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil. Anesthesiology 91, 144-155 (1999).
42. Ramsay, S.C. et al. Changes in global cerebral blood flow in humans: effect on regional cerebral blood flow during a neural activation task. J. Physiol. 471, 521-534 (1993).
43. 2 in humans. J. Appl. Physiol. 81, 1084-1095 (1996).
44. Corfield, D.R., Murphy, K., Josephs, O., Adams, L. & Turner, R. Does hypercapnia-induced cerebral vasodilation modulate the hemodynamic response to neural activation? NeuroImage 13 (6 Part 1), 1207-1211 (2001).
45. Hoge, R.D., Atkinson, J., Gill, B., Crelier, G.R., Marrett, S. & Pike, G.B. Investigation of BOLD signal dependence on cerebral blood flow and oxygen consumption: the deoxyhemoglobin dilution model. Magn. Reson. Med. 42, 849-863 (1999).
46. Bandettini, P.A. & Wong, E.C. A hypercapnia-based normalization method for improved spatial localization of human brain activation with fMRI. NMR Biomed. 10, 197-203 (1997).
47. Lötsch, J., Skarke, C., Schneider, A., Hummel, T. & Geisslinger, G. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Clin. Pharmacol. Ther. 78, 278-287 (2005).
48. Latasch, L., Teichmuller, T., Dudziak, R. & Probst, S. Antagonisation of fentanyl-induced respiratory depression by nalbuphine. Acta Anaesthesiol. Belg. 40, 35-40 (1989).
49. Becerra, L., Harter, K., Gonzalez, R.G. & Borsook, D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth. Analg. 103, 208-216 (2006).
50. Shafer, S.L., Varvel, J.R., Aziz, N. & Scott, J.C. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology 73, 1091-1102 (1990).
51. Scott, J.C., Ponganis, K.V. & Stanski, D.R. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 62, 234-241 (1985).
52. Kobal, G. Pain-related electrical potentials of the human nasal mucosa elicited by chemical stimulation. Pain 22, 151-163 (1985).
53. Thürauf, N., Hummel, T., Kettenmann, B. & Kobal, G. Nociceptive and reflexive responses recorded from the human nasal mucosa. Brain Res. 629, 293-299 (1993).
54. Hari, R. & Forss, N. Magnetoencephalography in the study of human somatosensory cortical processing. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354, 1145-1154 (1999).
55. Lötsch, J., Ahne, G., Kunder, J., Kobal, G. & Hummel, T. Factors affecting pain intensity in a pain model based upon tonic intranasal stimulation in humans. Inflamm. Res. 47, 446-450 (1998).
56. Lotsch, J., Stuck, B. & Hummel, T. The human mu-opioid receptor gene polymorphism 118A>G decreases cortical activation in response to specific nociceptive stimulation. Behav. Neurosci. 120, 1218-1224 (2006).
57. Boyle, J.A., Heinke, M., Gerber, J., Frasnelli, J. & Hummel, T. Cerebral activation to intranasal chemosensory trigeminal stimulation. Chem. Senses 32, 343-353 (2007).
58. Iannilli, E., Gerber, J., Frasnelli, J. & Hummel, T. Intranasal trigeminal function in subjects with and without an intact sense of smell. Brain Res. 1139, 235-244 (2007).
59. Hummel, T., Gruber, M., Pauli, E. & Kobal, G. Chemo-somatosensory event-related potentials in response to repetitive painful chemical stimulation of the nasal mucosa. Electroencephalogr. Clin. Neurophysiol. 92, 426-432 (1994).
60. Kobal, G., Hummel, T. & Hoesl, M. Pain-related electrical evoked potentials by chemical stimuli: effects of fentanyl. In Advances in Pain Research and Therapy (ed. Lipton, S.) 95-98 (Raven Press: New York, 1989).
61. Oertel, B.G. et al. The partial 5-hydroxytryptamine(1A) receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans. Clin. Pharmacol. Ther. 81, 59-68 (2007).
62. Friston, K.J., Fletcher, P., Josephs, O., Holmes, A., Rugg, M.D. & Turner, R. Event-related fMRI: characterizing differential responses. NeuroImage 7, 30-40 (1998).
63. Cusack, R., Brett, M. & Osswald, K. An evaluation of the use of magnetic field maps to undistort echo-planar images. NeuroImage 18, 127-142 (2003).
64. Worsley, K.J. & Friston, K.J. Analysis of fMRI time-series revisited - again. NeuroImage 2, 173-181 (1995).
65. Friston, K.J. et al. Analysis of fMRI time-series revisited. NeuroImage 2, 45-53 (1995).
66. Friston, K.J., Holmes, A.P., Worsley, K.J., Poline, J.B., Frith, C.D. & Frackowiak, R.S. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2, 189-210 (1995).
67. Friston, K.J., Ashburner, J., Frith, C.D., Poline, J.B., Heather, J.D. & Frackowiak, R.S. Spatial registration and normalization of images. Hum. Brain Mapp. 3, 165-189 (1995).
68. Evans, A.C., Collins, D.L., Mills, S.R., Brown, E.D., Kelly, R.L. & Peters, T.M. 3D statistical neuroanatomical models from 305 MRI volumes. Proc. IEEE Nucl. Sci. Symp. Med. Imaging 3, 1813-1817 (1993).
69. 2, F and t fields. Adv. Appl. Probab. 26, 13-42 (1994).
70. Loring, D.W. et al. Now you see it, now you don't: statistical and methodological considerations in fMRI. Epilepsy Behav. 3, 539-547 (2002).
71. Tzourio-Mazoyer, N. et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15, 273-289 (2002).